Post-chemotherapy cognitive impairment in patients with B-cell non-Hodgkin lymphoma: a first comprehensive approach to determine cognitive impairments after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or rituximab and bendamustine

Publikationen: Beitrag in FachzeitschriftZeitschriftenaufsätzeForschungBegutachtung

Standard

Harvard

APA

Vancouver

Bibtex

@article{36ba0d3ff5954a4a9444742551ae4691,
title = "Post-chemotherapy cognitive impairment in patients with B-cell non-Hodgkin lymphoma: a first comprehensive approach to determine cognitive impairments after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or rituximab and bendamustine",
abstract = "To assess the effects of chemoimmunotherapy on post-chemotherapy cognitive impairments (PCCI) in patients with B-cell non-Hodgkin lymphoma (NHL), we used objective and subjective measures of cognitive functions in combination with serum parameters and neuroelectric recordings. Self-perceived status of cognition, fatigue and emotional functioning were reduced in patients (n = 30) compared to healthy controls (n = 10). Cognitive performance was impaired in patients with NHL compared to controls and a norm sample (n = 1179). PCCI was more severe in patients treated with rituximab and bendamustine (BR) than in patients who received R in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) polychemotherapy (R-CHOP). Individual alpha peak frequency and serum brain-derived neurotrophic factor (BDNF) levels in patients with NHL correlated with accuracy in the objective cognition test. Higher serum interleukin-6 (IL-6) concentrations were associated with higher fatigue levels. Patients with NHL and especially those who were treated with BR were affected by PCCI. BDNF and IL-6 might be involved in the pathogenesis of PCCI and fatigue.",
author = "Philipp Zimmer and Andreas Mierau and Wilhelm Bloch and Str{\"u}der, {Heiko Klaus} and Thorben H{\"u}lsd{\"u}nker and Alexander Schenk and Leonie Fiebig and Freerk Baumann and Moritz Hahn and Nina Reinart and Michael Hallek and Thomas Elter",
year = "2014",
month = "6",
day = "5",
doi = "10.3109/10428194.2014.915546",
language = "English",
pages = "1--6",
journal = "Leukemia & lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",

}

RIS

TY - JOUR

T1 - Post-chemotherapy cognitive impairment in patients with B-cell non-Hodgkin lymphoma

T2 - a first comprehensive approach to determine cognitive impairments after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or rituximab and bendamustine

AU - Zimmer, Philipp

AU - Mierau, Andreas

AU - Bloch, Wilhelm

AU - Strüder, Heiko Klaus

AU - Hülsdünker, Thorben

AU - Schenk, Alexander

AU - Fiebig, Leonie

AU - Baumann, Freerk

AU - Hahn, Moritz

AU - Reinart, Nina

AU - Hallek, Michael

AU - Elter, Thomas

PY - 2014/6/5

Y1 - 2014/6/5

N2 - To assess the effects of chemoimmunotherapy on post-chemotherapy cognitive impairments (PCCI) in patients with B-cell non-Hodgkin lymphoma (NHL), we used objective and subjective measures of cognitive functions in combination with serum parameters and neuroelectric recordings. Self-perceived status of cognition, fatigue and emotional functioning were reduced in patients (n = 30) compared to healthy controls (n = 10). Cognitive performance was impaired in patients with NHL compared to controls and a norm sample (n = 1179). PCCI was more severe in patients treated with rituximab and bendamustine (BR) than in patients who received R in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) polychemotherapy (R-CHOP). Individual alpha peak frequency and serum brain-derived neurotrophic factor (BDNF) levels in patients with NHL correlated with accuracy in the objective cognition test. Higher serum interleukin-6 (IL-6) concentrations were associated with higher fatigue levels. Patients with NHL and especially those who were treated with BR were affected by PCCI. BDNF and IL-6 might be involved in the pathogenesis of PCCI and fatigue.

AB - To assess the effects of chemoimmunotherapy on post-chemotherapy cognitive impairments (PCCI) in patients with B-cell non-Hodgkin lymphoma (NHL), we used objective and subjective measures of cognitive functions in combination with serum parameters and neuroelectric recordings. Self-perceived status of cognition, fatigue and emotional functioning were reduced in patients (n = 30) compared to healthy controls (n = 10). Cognitive performance was impaired in patients with NHL compared to controls and a norm sample (n = 1179). PCCI was more severe in patients treated with rituximab and bendamustine (BR) than in patients who received R in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) polychemotherapy (R-CHOP). Individual alpha peak frequency and serum brain-derived neurotrophic factor (BDNF) levels in patients with NHL correlated with accuracy in the objective cognition test. Higher serum interleukin-6 (IL-6) concentrations were associated with higher fatigue levels. Patients with NHL and especially those who were treated with BR were affected by PCCI. BDNF and IL-6 might be involved in the pathogenesis of PCCI and fatigue.

U2 - 10.3109/10428194.2014.915546

DO - 10.3109/10428194.2014.915546

M3 - Journal articles

C2 - 24738942

SP - 1

EP - 6

JO - Leukemia & lymphoma

JF - Leukemia & lymphoma

SN - 1042-8194

ER -

ID: 64670